GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuCell Corp (NAS:ICCC) » Definitions » EV-to-FCF
中文

ImmuCell (ImmuCell) EV-to-FCF : -8.33 (As of Apr. 25, 2024)


View and export this data going back to 1995. Start your Free Trial

What is ImmuCell EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ImmuCell's Enterprise Value is $54.70 Mil. ImmuCell's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.57 Mil. Therefore, ImmuCell's EV-to-FCF for today is -8.33.

The historical rank and industry rank for ImmuCell's EV-to-FCF or its related term are showing as below:

ICCC' s EV-to-FCF Range Over the Past 10 Years
Min: -89.7   Med: -14.25   Max: 122.61
Current: -8.33

During the past 13 years, the highest EV-to-FCF of ImmuCell was 122.61. The lowest was -89.70. And the median was -14.25.

ICCC's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 4.22 vs ICCC: -8.33

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-25), ImmuCell's stock price is $5.04. ImmuCell's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.750. Therefore, ImmuCell's PE Ratio for today is At Loss.


ImmuCell EV-to-FCF Historical Data

The historical data trend for ImmuCell's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuCell EV-to-FCF Chart

ImmuCell Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -31.80 -16.59 -37.48 -9.77 -8.40

ImmuCell Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.77 -5.69 -5.45 -6.56 -8.40

Competitive Comparison of ImmuCell's EV-to-FCF

For the Biotechnology subindustry, ImmuCell's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmuCell's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuCell's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where ImmuCell's EV-to-FCF falls into.



ImmuCell EV-to-FCF Calculation

ImmuCell's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=54.699/-6.566
=-8.33

ImmuCell's current Enterprise Value is $54.70 Mil.
ImmuCell's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ImmuCell  (NAS:ICCC) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

ImmuCell's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=5.04/-0.750
=At Loss

ImmuCell's share price for today is $5.04.
ImmuCell's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.750.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


ImmuCell EV-to-FCF Related Terms

Thank you for viewing the detailed overview of ImmuCell's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmuCell (ImmuCell) Business Description

Traded in Other Exchanges
Address
56 Evergreen Drive, Portland, ME, USA, 04103
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured to prevent scours in newborn calves. It has two segments Scours and Mastitis. The company generates the majority of its revenue from the United States.
Executives
Bryan K. Gathagan director 56 EVERGREEN DRIVE, PORTLAND ME 04103
David Cunningham director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Gloria F Basse director 56 EVERGREEN DRIVE, PORTLAND ME 04103
David Scott Tomsche director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Steven T. Rosgen director C/O IMMUCELL CORPORATION, 56 EVERGREEN DR., PORTLAND ME 04103
Norman H Pessin other: See Explanation of Responses C/O LEVY, HARKINS & CO., INC., 366 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Brian L. Pessin other: See Explanation of Responses 310 EAST 75TH STREET, APT. 2A, NEW YORK NY 10021
Joseph H Crabb director, officer: Vice President and CSO IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Elizabeth Luttrell Williams officer: Vice Pres. of Mfg Operations C/O IMMUCELL CORPORATION, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Jonathan E Rothschild director, 10 percent owner C/O IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Linda Rhodes director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Paul R Wainman director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Michael F Brigham director, officer: President and CEO IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Bobbi Jo Kunde other: Director of Sales and Marketin 56 EVERGREEN DRIVE, PORTLAND ME 04103
Robert C Bruce director 56 EVERGREEN DRIVE, PORTLAND ME 04103